Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017; 377: 122-131.

Published: 30th September 2017

Authors: von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al.

Conclusion

This study included 4805 women. The addition of pertuzumab reduced disease recurrence (hazard ratio 0.81, 95 per cent confidence interval 0.66 to 1.0, P=0.045). The effect was greater in women with node positive disease (0.77, 0.62 to 0.96, P=0.02).

Pubmed Link

Your comments

0 Comments